Background: Direct oral anticoagulants (DOACs) may cause false results of activated protein C resistance (APC-R) ratio. DOAC-Remove, a new reagent based on activated carbon, has been designed to eliminate the interference of DOACs on coagulation assays. The aim of the study was to investigate whether the use of DOAC-Remove enables to determine APC-R in patients treated with DOACs. Methods: We assessed 74 venous thromboembolism (VTE) patients, including 25 on rivaroxaban, 25 on apixaban and 24 taking dabigatran. APC-R was determined using the Russell Viper Venom Time (RVVT)-based clotting test. APC-R and DOAC concentrations were tested at baseline and following DOAC-Remove. Thrombophilia, including factor V Leiden (FVL) mutation was tested. Results: FVL mutation was found in 20 (27%) patients. The APC-R ratio at baseline was measurable in 43 patients (58.1%), including 20 (80%) on rivaroxaban, 19 (76%) on apixaban and four (16.7%) on dabigatran. In patients with measurable APC-R at baseline, the ratio >2.9 was found in 23 patients (53.5%). In 16 (37.2%) subjects APC-R ratio <1.8 suggested FVL mutation which was genetically confirmed. Four (9.3%) FVL carriers on dabigatran showed negative/equivocal APC-R results. In 11 (14.9%) patients taking rivaroxaban or apixaban, in whom blood was collected 2-5 h since the last dose, we observed unmeasurable APC-R. DOAC-Remove almost completely eliminated all plasma DOACs. After addition of DOAC-Remove all APC-R ratios were measurable. In four FVL carriers on dabigatran with false negative APC-R, DOAC-Remove resulted in APC-R ratios <1.8. Conclusions: DOAC-Remove effectively reduces DOACs concentration in plasma, which enables FVL testing using APC-R.
Introduction
Activated Protein C (APC) as a key regulator of the coagulation cascade acts by inactivation of both activated factor V (FVa) and FVIIIa [1] . In the Caucasian population, approximately 20%-60% of patients who experienced an episode of venous thromboembolism (VTE), have resistance to APC (APC-R) [2, 3] . The APC-R is defined as an abnormally reduced anticoagulant response to APC, based on an in vitro test and was described in 1993 by Dahlbäck et al. [4] . In 1994, Bertina and co-workers [5] reported that the APC-R is associated with a point mutation in the FV gene, known as factor V Leiden (FVL, Arg506Gln) [5] . Approximately 95% of APC-R is caused by the FVL mutation [6] , with a small contribution of Arg306Thr (FV Cambridge), Arg306Gly (FV Hong Kong) and Ile359Thr (FV Liverpool) [6, 7] , PC and protein S (PS) deficiency, increased FVIII activity, elevated homocysteine levels, prothrombin G20210A mutation, the presence of antiphospholipid antibodies, pregnancy or cancer [8, 9] .
The APC-R ratio may be interfered with by the use of oral contraceptives, hormone replacement therapy, vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs) [10] [11] [12] [13] . The most frequently used DOAC in Poland, as well as in many European countries is rivaroxaban [14] . Rivaroxaban and apixaban are selective, direct factor Xa (FXa) inhibitors, while dabigatran is a direct thrombin inhibitor [15] . It has been demonstrated that dabigatran either in the ex vivo and in vitro studies interfered with APC-R ratios in FVL-positive and -negative subjects, overestimating results [16] . Falsely increased [17] [18] [19] and decreased [13] APC-R ratios were reported on rivaroxaban. The APC-R ratio was also increased by apixaban, especially in the activated partial thromboplastin time (APTT)-based assay [20] .
It is recommended in thrombophilia screening to perform the APC-R assays first, and in the case of positive or borderline results to proceed to genetic determination [7, 21, 22] . Due to the fact that APC-R is sensitive for many interferences [23] , interpretation of this assay as a screening test in the diagnosis of thrombophilia is challenging. DOAC-Remove (5-Diagnostics, Basel, Switzerland) based on activated carbon is intended for removal of all types of DOACs from human citrated plasma samples to eliminate their interference on routine coagulation assays. It has been demonstrated that the use of similar reagent named DOAC-Stop (Haematex Research, Sydney, Australia) resulted in appropriate lupus anticoagulant testing in up to 97% of VTE patients [24] .
The aim of this study was to investigate whether DOAC-Remove can be helpful to determine reliable APC-R ratios in real-life VTE patients treated with DOACs during thrombophilia screening.
Materials and methods

Patients
We studied 74 consecutive patients with VTE receiving DOACs, referred to the Centre for Coagulation Disorders in the John Paul II Hospital, Krakow, Poland for thrombophilia screening. Patients treated with rivaroxaban, apixaban and dabigatran were eligible.
All patients fulfilled the diagnostic criteria for VTE prior to enrolment. Data on demographics, medical history and current treatment were collected using a standardized questionnaire. The diagnosis of deep vein thrombosis (DVT) was established by a positive finding of color duplex sonography (visualization of an intraluminal thrombus in calf, popliteal, femoral or iliac veins). The diagnosis of pulmonary embolism (PE) was based on the presence of typical symptoms and positive results of high-resolution spiral computed tomography. An unprovoked VTE episode was defined as having no history of cancer, surgery requiring general anesthesia, major trauma, plaster cast, immobilization or hospitalization in the past month, oral contraceptive use or hormone replacement therapy and pregnancy or delivery in the past 3 months. Arterial hypertension was diagnosed based on a history of hypertension (blood pressure >140/90 mmHg) or preadmission antihypertensive treatment. Antiphospholipid syndrome (APS) was diagnosed according to the revised classification criteria [25, 26] .
Smoking was defined as the use of one or more cigarettes per day.
All eligible patients had documented VTE treated with DOACs for at least 2 months prior to the enrolment. The exclusion criteria for VTE subjects were: use of anticoagulants other than DOACs, known malignancy, signs of acute infection, pregnancy or postpartum period and end-stage kidney disease.
The Jagiellonian University Medical College Ethical Committee approved the study and participants provided written informed consent in accordance with the Declaration of Helsinki.
Laboratory analysis
After an overnight fast venous blood drawn from the antecubital vein into citrated tubes (9:1 of 0.106 M sodium citrate) was centrifuged at 2500 g at 20 °C for 20 min, and stored in small aliquots at −80 °C until analysis. To determine creatinine and alanine aminotransferase (ALT), routine laboratory assays were used. APTT was performed using a BCS-XP analyzer with commercially available reagents (Siemens Healthcare Diagnostics, Marburg, Germany). FVIII, PC, PS and antithrombin were performed on the BCS-XP analyzer according to the manufacturer's instructions (all from Siemens; Coagulation Factor VIII Deficient Plasma for FVIII, Berichrom Protein C for PC, Innovance Free protein S Ag for protein S and Innovance Antithrombin for AT). Fibrinogen was measured by the von Clauss method (Instrumentation Laboratory, Bedford, MA, USA). Immunoturbidimetric assay was used to determine plasma D-dimer (Siemens). Rivaroxaban and apixaban concentrations were measured by the anti-factor Xa chromogenic assay (Biophen DiXaI, Hyphen Biomed, Neuilly-sur-Oise, France) with specific calibrators, while plasma concentration of dabigatran was determined using the Hemoclot thrombin inhibitor assay (Hyphen Biomed, Neuilly-sur-Oise, France) according to the manufacturer's instruction. DOAC values after DOAC-Remove were evaluated using reagents for measuring low concentration of the drugs with cut-off for rivaroxaban and apixaban 3 ng/mL and for dabigatran 5 ng/mL. APC-R was determined using the Russell Viper Venom Time (RVVT)-based functional clotting test (ProC Ac R assay, Siemens, Marburg, Germany). The clotting time (CT) of the tested plasma with the activator (Agkistrodon contortrix contortrix venom) was compared with the CT without activator. Results were reported as a ratio. The expected APC-R ratio for non-FVL carriers was above 2.9, while for FVL carriers (both GA and AA genotypes) was lower than 1.8. APC-R ratios between 1.8 and 2.9 were classified as equivocal and need further investigation [12] . Samples in which clotting time exceeded 200 s were unmeasurable.
FVL mutation was detected by the real-time PCR with the use of Taq Man genetic probes (Life Technologies Co., Carlsbad, CA, USA). The prothrombin G20210A polymorphism was determined by the restriction fragment length polymorphism (PCR/RFLP) analysis with the use of HindIII restrictase (Fermentas, Hnover, MD, USA).
Each patient's plasma was tested at baseline and following treatment with DOAC-Remove (5-Diagnostics AG, Basel, Switzerland) according to the manufacturer's instruction. One tablet of DOAC-Remove was added into 1 ml of citrated plasma, mixed gently using rotating shaker for 5 min and centrifuged for 2 min at 2000 g at room temperature. Plasma supernatants were carefully removed avoiding resuspension of the precipitate and used for the APC-R testing.
Statistical analysis
Categorical variables are presented as numbers and percentages. Categorical variables were analyzed by Pearson's chi-square (χ 2 ) or Fisher's exact test. Continuous variables are expressed as mean ± standard deviation (SD) or median with quartiles Q1-Q3. Normality of the data was assessed using the Shapiro-Wilk's test. The groups were compared using Student's test for normally distributed continuous variables and for non-normally distributed continuous variables the Mann-Whitney U-test was used. Analysis of covariance (ANCOVA) was used to compare continuous variables across >2 groups. Multiple comparisons were performed with the Tukey-Kramer adjustment. Associations between nonparametric and parametric variables were assessed by Spearman's and Pearson's tests, respectively. Values of p < 0.05 were considered statistically significant. All statistical analyses were performed using JMP ® Version 13.1.0 and SAS 9.4 (SAS Institute Inc.).
Results
A total of 74 middle-aged VTE patients were analyzed ( (Table 1) . No intergroup differences were found in laboratory variables, except for higher fibrinogen level observed in patients taking dabigatran without FVL (p = 0.03) compared with two other groups.
Median plasma rivaroxaban concentration evaluated 2-24 h since the last dose intake was 112 (59-315) ng/mL. Median plasma apixaban concentration was 98 (76-138) ng/mL in samples obtained 1.25-13 h after the last dose intake. Median plasma dabigatran concentration assessed 2.5-24 h after drug administration was 52 (36-79.3) ng/mL.
For each DOAC we observed an association between the drug concentrations and the time from the last dose intake (r = −0.75, p = 0.00002 for rivaroxaban; r = −0.48, p = 0.018 for apixaban; and r = −0.42, p = 0.045 for dabigatran).
The prevalence of FVL and prothrombin G20210A mutation was similar in all groups (all p > 0.05, Table 1 ). An FVL mutation was found in 20 (27%) patients, including a homozygous man (AA), while PT G20210A mutation was reported in two heterozygous subjects.
APC-R ratio at baseline
The APC-R ratio at baseline was measurable in 43 patients (58.1%), including 20 (80%) on rivaroxaban, 19 (76%) on apixaban and four (16.7%) on dabigatran. In 31 (41.9%) cases the clotting time exceeded 200 s and APC-R was unmeasurable ( Table 2 ). Among patients with unmeasurable APC-R, 20 (64.5%) were treated with dabigatran, six (19.4%) with apixaban and five (16.1%) with rivaroxaban (Table 3 ). In VTE patients with measurable APC-R at baseline, the ratio higher than 2.9 (non-APC-R patients) was found in 23 patients (53.5%). In 16 subjects (37.2%; nine on rivaroxaban and seven on apixaban) the APC-R ratio was below 1.8, suggesting FVL mutation which was genetically confirmed. However, four (9.3%) FVL carriers, all on dabigatran, showed either APC-R negative (n = 1, ratio >2.9) or equivocal (n = 3, ratio 1.8-2.9) results. None of those patients had other thrombophilias (Table 4) .
At baseline there were no correlations between plasma DOAC concentrations and APC-R ratios, regardless of FVL. RVV clotting time without, but not with the activator (A. contortrix contortrix venom) correlated with plasma DOACs concentrations (r = 0.6, p < 0.001).
Unmeasurable APC-R ratios were observed in 41.7% of patients taking rivaroxaban and 37.5% on apixaban in whom blood was drawn up to 5 h since the last dose of drug intake (Table 5 ). In patients treated with dabigatran, unmeasurable APC-R was observed in most patients, regardless the time since the last dose intake (0-5 h in 85.7% of patients, >5-12 h in 75% of patients, and >12-24 h in 88.9% of patients) ( Table 5 ).
APC-R ratio after DOAC-Remove
DOAC-Remove reduced DOAC concentrations by almost 100% for rivaroxaban (all <3 ng/mL, p < 0.0001), apixaban (<3-7 ng/mL, p < 0.0001), and dabigatran (all <5 ng/mL, p < 0.0001). After the use of the DOAC-Remove, the APC-R ratios were measurable in all 74 (100%) samples (Figure 1 ). In 54 (73%) cases, including 31 previously unmeasurable samples ( Table 2) , APC-R ratios were higher than 2.9 and suggesting absence of FVL mutation, while in 20 subjects (27%) with FVL we recorded resistance to APC reflected by a ratio lower than 1.8 ( Table 2 ). In four FVL carriers treated with dabigatran and false negative APC-R at baseline, DOAC-Remove resulted in APC-R ratios <1.8 (Table 4 ).
We did not observe differences in median APC-R ratio at baseline and following DOAC-Remove in patients with measurable APC-R treated with rivaroxaban and apixaban regardless of FVL status (Table 3 ). In FVL patients receiving dabigatran (n = 4) the APC-R ratios after DOAC-Remove were 53.8% lower than at baseline (p = 0.03).
Discussion
Our observations confirmed that addition of the DOAC-Remove to plasma samples of VTE patients taking DOACs, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 22 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 20 22 [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 0.95 21 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 21 31 [27, 28] . However, the authors did not include patients with thrombophilias, especially those with FVL and they were not able to confirm the utility of APC-R testing after DOAC-Stop in patients suspected for thrombophilia. Therefore, our study is the first to show that DOAC-Remove enables FVL testing using APC-R, which was genetically confirmed. Despite known recommendations [23] , in everyday practice patients are often referred for thrombophilia screening during anticoagulation treatment, which may result in false results of routine coagulation assays [15, 29, 30] . As it is known that APC-R ratio may be affected by the use of DOACs [16] [17] [18] [19] [20] , the utility of APC-R as FVL mutation screening test is limited. Therefore, to avoid interference /AA)  16   3   1  0  20   20   0   0  0  20  Total   16   4   23  31  74   20   0   54  0  74 APC-R, activate protein C resistance; DOAC, direct oral anticoagulants FVL, factor V Leiden; UM, unmeasurable ratio/clotting outside the measurable range. during the assessment of APC-R, it is recommended to collect blood directly before drug administration or after discontinuation of DOACs [31] .
In our study, we did not observe in FVL patients treated with rivaroxaban or apixaban incorrect APC-R ratios at baseline. This might be explained by different mechanisms of action of those drugs. Rivaroxaban or apixaban as a FXa inhibitors interrupt the intrinsic and extrinsic coagulation cascade and indirectly inhibit thrombin production and thrombus formation, while dabigatran as a direct thrombin inhibitor converts soluble fibrinogen to fibrin triggering thrombus formation. Interestingly, we reported that in non-FVL carriers' APC-R ratios were unmeasurable independently of the type of DOACs. In patients taking rivaroxaban or apixaban unmeasurable APC-R ratios were observed rather in the peak than in the through drug concentrations. On the other hand, in patients taking dabigatran APC-R ratios were affected regardless of the time since the drug intake. Recent study by Gessoni and coworkers [16] , have shown that dabigatran affects APC-R ratio leading to misclassification of FVL heterozygous carriers. Similarly, we reported four FVL carriers on dabigatran with overestimated APC-R ratios at baseline and none of those patients had coagulation factors deficiency or increased FVIII activity. However, we cannot exclude other rare mutations in the FV gene such as Arg306Thr or Ile359Thr. We extended the observation by Gessoni et al. by showing that dabigatran causes unmeasurable APC-R ratios at baseline in non-FVL carriers, also at low dabigatran concentrations in the RVVT-based clotting test.
DOAC-Remove has been developed to determine coagulation parameters in patients on DOACs, without interruption of these drugs and/or use of heparins for a few days to ensure reliable results of coagulation assays. In our study addition of DOAC-Remove provided measurable and appropriate results for APC-R ratios in patients taking DOACs.
It should be underlined that the assessment of APC-R in VTE patients taking DOACs is not recommended in routine laboratory work [23] , the use of DOAC-Remove can provide reliable results of APC-R in patients with high thrombotic risk in whom interruption of anticoagulation therapy may be dangerous. Further studies are needed to evaluate the utility of DOAC-Remove in APC-R testing in patients anticoagulated with DOACs to minimize the cost of genetic diagnostics of thrombophilias.
Study limitations
This study has several limitations. First, the group size was limited in particular in subgroup analysis and the results should be interpreted with caution, requiring validation in larger populations. Second, we determined resistance to APC at baseline and following DOAC-Remove using RVVT-based functional clotting test routinely used in our laboratory, which is analogous to the APTT-based method, except that RVVT eliminates an influence of FVIII, FIX, FXI and FXII on APC-R ratio [16] . APC-R may be also tested using the prothrombinase-based method in which the role of FXa is replaced by noscarin, probably eliminating the influence of FXa inhibitors [16, 32] . The use of DOAC-Stop in patients on dabigatran decreased the APC-R ratios [28] . On the other hand, the effect of DOACs on APTT-based APC-R ratios is similar to the method based on the RVVT. Thus, theoretically, the use of DOAC-Remove would result in reliable APC-R ratios in anticoagulated patients.
Further studies are needed to confirm the DOAC-Remove utility for APC-R testing, regardless the method used.
Conclusions
DOAC-Remove reduces plasma DOAC concentrations and allows to obtain appropriate APC-R ratios in VTE patients on DOACs. Although, the APC-R testing in patients on DOACs is not recommended, DOAC-Remove appears to be useful in APC-R testing in patients with high thrombotic risk treated with DOACs.
